Wellmarker Bio is focused on developing first-in-class anticancer drugs that leverage predictive biomarkers to address unmet medical needs in cancer treatment. The company utilizes clinical data from one of South Korea's largest hospitals to enhance its research efforts. By identifying predictive biomarkers, Wellmarker Bio aims to determine a patient's potential response to specific therapies, which can significantly shorten the drug development timeline, reduce costs, and improve the success rates of new anticancer drugs. This innovative approach contrasts with traditional "one-size-fits-all" therapies, which often overlook individual biological differences and can lead to ineffective treatments and adverse side effects.

The company's research infrastructure includes specialized departments dedicated to target discovery, drug discovery, medicinal chemistry, and chemistry, manufacturing, and controls (CMC). With a workforce comprised of 80% R&D experts, Wellmarker Bio emphasizes an in-house approach to drug development. Their core technology focuses on optimizing drug development through the use of predictive biomarkers, which not only enhance the likelihood of successful drug approval but also facilitate precision medicine. By analyzing patient samples through various scientific methods, Wellmarker Bio aims to provide safer and more effective treatments tailored to individual patient profiles, ultimately contributing to a healthier future free from cancer.

South Korea

Wellmarker Bio is a spin-off company from Seoul Asan Medical Center(AMC), which is the largest and most renowned hospital in the Republic of Korea. We specialized in developing predictive biomarkers and first-in-class drugs through profound research know-hows and Research Institute that is comprised of Target discovery department, Drug discovery department, Medicinal chemistry department and CMC department.

Wellmarkerbio

Company Details